Brookline Capital Management Brokers Decrease Earnings Estimates for Immunic, Inc. (NASDAQ:IMUX)

Immunic, Inc. (NASDAQ:IMUX) – Stock analysts at Brookline Capital Management reduced their Q2 2024 earnings per share estimates for Immunic in a research report issued on Monday, May 20th. Brookline Capital Management analyst T. Bussian now anticipates that the company will post earnings per share of ($0.23) for the quarter, down from their previous estimate of ($0.22). Brookline Capital Management has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.95) per share. Brookline Capital Management also issued estimates for Immunic’s Q3 2024 earnings at ($0.23) EPS, Q4 2024 earnings at ($0.23) EPS and FY2024 earnings at ($0.91) EPS.

Separately, StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a research note on Saturday, April 27th.

Immunic Stock Performance

IMUX opened at $1.25 on Thursday. The stock’s 50 day moving average price is $1.29 and its 200-day moving average price is $1.27. Immunic has a one year low of $0.95 and a one year high of $3.11. The stock has a market cap of $112.60 million, a price-to-earnings ratio of -0.68 and a beta of 1.93.

Immunic (NASDAQ:IMUX) last released its earnings results on Thursday, February 22nd. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.03.

Hedge Funds Weigh In On Immunic

Hedge funds and other institutional investors have recently made changes to their positions in the company. RTW Investments LP raised its holdings in shares of Immunic by 0.9% in the 3rd quarter. RTW Investments LP now owns 4,335,255 shares of the company’s stock valued at $6,373,000 after purchasing an additional 40,796 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Immunic by 26.8% during the third quarter. Acadian Asset Management LLC now owns 757,250 shares of the company’s stock valued at $1,111,000 after buying an additional 159,973 shares during the last quarter. Gratus Capital LLC grew its stake in Immunic by 15.1% during the 4th quarter. Gratus Capital LLC now owns 1,941,454 shares of the company’s stock valued at $2,912,000 after purchasing an additional 254,999 shares during the last quarter. Sweet Financial Partners LLC purchased a new stake in Immunic in the fourth quarter valued at approximately $45,000. Finally, Innovis Asset Management LLC boosted its holdings in shares of Immunic by 46.3% in the 3rd quarter. Innovis Asset Management LLC now owns 272,457 shares of the company’s stock valued at $401,000 after acquiring an additional 86,217 shares during the last quarter. Institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.